Effect of Novel Antidiabetic Drug Combined With Angiotensin Receptor/Neprilysin Inhibitor on Urinary Protein
- Conditions
- Antidiabetic DrugsType 2 Diabetes
- Registration Number
- NCT05922852
- Lead Sponsor
- Peking University Third Hospital
- Brief Summary
The purpose of this study is to determine whether the combination of SGLT2i and ARNI in type 2 diabetic patients with combined albuminuria could reduce urinary protein more significantly than single agent.
- Detailed Description
This project is a single-center retrospective cohort study to obtain the biochemical index levels of urinary albumin creatinine ratio, urinary protein creatinine ratio, blood renal function, blood lipids, and blood glucose at the immediate, 3rd, 6th, and 12th month of cohort inclusion in each group of patients.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 1000
- Age greater than or equal to 18 years
- Clinical diagnosis of type 2 diabetes mellitus
- Immediate urine albumin creatinine ratio greater than 30mg/g
- Signed informed consent and available for follow-up
- severe renal insufficiency, i.e. eGFR ≤ 30ml/min/1.75m2
- clinical diagnosis of various acute and chronic urinary tract infections
- combined with various serious infectious diseases
- combined with acute complications of diabetes mellitus
- end-stage malignancy
- pregnancy and lactation
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method urinary protein changes 2023.03-2024.03 to determine whether the combination of SGLT2i and ARNI in type 2 diabetic patients with combined albuminuria could reduce urinary protein more significantly than single agent.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
Peking University Third Hospital, Beijing, Beijing 100191
🇨🇳Beijing, Beijing, China
Peking University Third Hospital
🇨🇳Beijing, Beijing, China